Among other things, doctors will be checking the metabolism of the drug in the children during the 24-week trial. It is turning out that kids are metabolizing protease inhibitors differently than adults. Preliminary results could be ready in eight to nine months. Patients in the protease inhibitor study will receive one of three treatment regimens, all involving a combination of HIV fighting drugs. About 240 children at up to 30 sites nationwide will participate in this study.
Side effects are likely to be more prevalent with the new class of drugs.
McKinney said adult patients have experienced nausea, vomiting, and fatigue. Ritanovir also inhibits the metabolism of other drugs, he said, so interaction of medication will be carefully monitored. He worries that compliance with the year-long regimented medication schedule may be difficult. It tastes awful, there are side effects, and the parents aren't going to see a big change in the child since the child's currently stable. But it's the newest ammunition and provides reason for hope.